0.3612 USD
+0 (+1.32%)
IXHL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. IXHL has a great financial health rating, but its profitability evaluates not so good. IXHL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- IXHL had negative earnings in the past year.
- IXHL had a negative operating cash flow in the past year.
- IXHL had negative earnings in each of the past 5 years.
- In the past 5 years IXHL always reported negative operating cash flow.
1.2 Ratios
- IXHL's Return On Assets of -59.56% is on the low side compared to the rest of the industry. IXHL is outperformed by 64.40% of its industry peers.
- The Return On Equity of IXHL (-60.88%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.56% | ||
| ROE | -60.88% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for IXHL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- IXHL has an Altman-Z score of 40.51. This indicates that IXHL is financially healthy and has little risk of bankruptcy at the moment.
- IXHL has a Altman-Z score of 40.51. This is amongst the best in the industry. IXHL outperforms 93.72% of its industry peers.
- There is no outstanding debt for IXHL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 40.51 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 47.51 indicates that IXHL has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 47.51, IXHL belongs to the top of the industry, outperforming 98.43% of the companies in the same industry.
- A Quick Ratio of 47.51 indicates that IXHL has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 47.51, IXHL belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 47.51 | ||
| Quick Ratio | 47.51 |
3. Growth
3.1 Past
- IXHL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.16%.
- Looking at the last year, IXHL shows a very strong growth in Revenue. The Revenue has grown by 616.67%.
- Measured over the past years, IXHL shows a very negative growth in Revenue. The Revenue has been decreasing by -36.33% on average per year.
EPS 1Y (TTM)-19.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.26%
Revenue 1Y (TTM)616.67%
Revenue growth 3Y-44.73%
Revenue growth 5Y-36.33%
Sales Q2Q%-100%
3.2 Future
- IXHL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.45% yearly.
- IXHL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1900.01% yearly.
EPS Next Y97.08%
EPS Next 2Y42.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for IXHL. In the last year negative earnings were reported.
- IXHL is valuated cheaply with a Price/Forward Earnings ratio of 5.73.
- Based on the Price/Forward Earnings ratio, IXHL is valued cheaply inside the industry as 94.76% of the companies are valued more expensively.
- IXHL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 24.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.73 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- IXHL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- IXHL's earnings are expected to grow with 42.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.45%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for IXHL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:IXHL (1/22/2026, 12:21:20 PM)
0.3612
+0 (+1.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14
Earnings (Next)02-12 2026-02-12
Inst Owners1.07%
Inst Owner Change-0.52%
Ins Owners12.79%
Ins Owner Change91.78%
Market Cap125.06M
Revenue(TTM)86.00K
Net Income(TTM)-46.88M
AnalystsN/A
Price TargetN/A
Short Float %5.05%
Short Ratio0.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)94.86%
EPS NY rev (1m)0%
EPS NY rev (3m)97.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.73 | ||
| P/S | 1454.17 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.62 | ||
| P/tB | 1.62 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.36
EYN/A
EPS(NY)0.06
Fwd EY17.44%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.56% | ||
| ROE | -60.88% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 11.63% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 47.51 | ||
| Quick Ratio | 47.51 | ||
| Altman-Z | 40.51 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.26%
EPS Next Y97.08%
EPS Next 2Y42.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)616.67%
Revenue growth 3Y-44.73%
Revenue growth 5Y-36.33%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y1900.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.33%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
INCANNEX HEALTHCARE INC / IXHL FAQ
What is the ChartMill fundamental rating of INCANNEX HEALTHCARE INC (IXHL) stock?
ChartMill assigns a fundamental rating of 4 / 10 to IXHL.
Can you provide the valuation status for INCANNEX HEALTHCARE INC?
ChartMill assigns a valuation rating of 4 / 10 to INCANNEX HEALTHCARE INC (IXHL). This can be considered as Fairly Valued.
What is the profitability of IXHL stock?
INCANNEX HEALTHCARE INC (IXHL) has a profitability rating of 0 / 10.